GlassScriptPhysician profile
Chad W Rossitter
NPI 1386961308
$7,220.29
in general payments reported to CMS, 2019-2025
23 companies · $1,020 in 2025
The $1,020 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $480 · 2021: $2,215 · 2022: $700 · 2023: $650 · 2024: $1,279 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,869 · Education: $80.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,868.61 |
| Education | $80.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $1,450.02 | 2021 | |
| Mallinckrodt Hospital Products INC. | $933.83 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $910.22 | 2019-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $861.95 | 2019-2025 | Veltassa, Korsuva |
| Ani Pharmaceuticals, INC. | $681.20 | 2022-2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $530.07 | 2019-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $499.78 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Genzyme Corporation | $232.45 | 2023-2025 | |
| Nxstage Medical, INC. | $168.47 | 2023 | Nxstage System One, Liberty Select Cycler |
| Amgen INC. | $167.55 | 2019-2025 | Krystexxa |
| Mallinckrodt Enterprises LLC | $121.16 | 2019 | |
| Calliditas Therapeutics US INC. | $110.74 | 2023-2025 | Tarpeyo |
| Medtronic, INC. | $101.30 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $80.60 | 2024-2025 | |
| Glaxosmithkline, LLC. | $78.20 | 2024-2025 | Arexvy, Shingrix, Benlysta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $76.46 | 2019-2024 | Vafseo, Auryxia |
| Vertex Pharmaceuticals Incorporated | $52.58 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.79 | 2021-2022 | |
| Scpharmaceuticals INC. | $47.74 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $27.62 | 2019-2020 | |
| Strongbridge US INC. | $15.20 | 2020 | |
| Athena Bioscience, LLC | $13.37 | 2023 | Nexiclon Xr |
| Allergan, INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Rossitter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.